https://www.selleckchem.com/pr....oducts/Novobiocin-so
This cohort included 218 950 patients with NASH (study group) and 30 493 574 patients without NASH (control group). The study group patients aged 57.3 ± 0.10 years (59.4% females) comparing to 54.5 ± 0.11 years (57.1% female) in the control group. HCC prevalence in subjects with NASH was 0.50% [95% confidence interval (CI) 0.41-0.59] compared to 0.21% (95% CI 0.20-0.23) in subjects without NASH (P less then 0.001). After adjusting for age, gender, smoking, alcohol use, obesity, hepatitis C virus, hepatitis B virus
Like
Comment
Share
